New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care; Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country; Novartis (www.Novartis.com) plans to roll the program out to a total of 10 African countries by 2022; Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five.
Novartis
Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in the world.